A three judge panel for the Ninth Circuit Court of Appeals has denied a petition filed by the Hemp Industries Association challenging the DEA’s authority to establish a new administrative drug code specifically for marijuana extracts. Petitioners say that will appeal the ruling.
The use of the naturally occurring cannabinoid CBD (cannabidiol) possesses no likely abuse potential and therefore should not be subject to new international scheduling restrictions, according to recommendations finalized today by the World Health Organization’s Expert Committee on Drug Dependence.
The use of the naturally occurring cannabinoid CBD is safe, well tolerated, and is not associated with any significant adverse public health effects, according to the findings of a preliminary report compiled by the World Health Organization’s Expert Committee on Drug Dependence. The agency is in the process of considering whether to place CBD within the agency’s international drug scheduling code.
The US Drug Enforcement Administration has publicly reiterated its position that cannabidiol, a non-psychotropic cannabinoid, is properly categorized under federal law as a schedule I controlled substance — meaning that, by definition, it possesses “a high potential for abuse,” “no currently accepted medical use in treatment in the United States,” and lacks “accepted safety … under medical supervision.”
Oral CBD administration is associated with reduced blood pressure in healthy volunteers, according to clinical trial data published online in the Journal of Clinical Investigation.
Some republican lawmakers in Wisconsin are reconsidering their position on marijuana reforms during the 2017 legislative session.
Members of Congress this week heard testimony on the state of marijuana research, and leading members of the US Senate introduced legislation to potentially reclassify CBD. A medical marijuana initiative in Montana qualified for the November ballot and Governors in three states signed marijuana related bills into law. Click here to get this week’s latest marijuana news and to find out how you can #TakeAction.
The administration of cannabis oil extracts high in cannabidiol reduces seizure frequency in children with intractable epilepsy, according to clinical data published online ahead of print in the journal Seizure. Investigators reported: “CBD treatment yielded a significant positive effect on seizure load. Most of the children (89 percent) reported reduction in seizure frequency. … In addition, we observed improvement in behavior and alertness, language, communication, motor skills and sleep.”
The administration of oral cannabis extracts is associated with the mitigation of seizures in adolescents with epilepsy, according to clinical data published this month in the journal Epilepsy & Behavior. Authors reported that 57 percent of subjects showed some level of improvement in seizure control while 33 percent reported a greater than 50 percent reduction in seizure frequency.